Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure

Movement Disorders

Volumn 18, Issue 5, 2003, Pages 487-495

  Smith, Lance A ^a   Jackson, Michael J ^a   Hansard, Matthew J ^a   Maratos, Eleni ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dyskinesia; Entacapone; L dopa; MPTP; Primates

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR; ENTACAPONE; LEVODOPA; POSTSYNAPTIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; BASAL GANGLION; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG DECOMPOSITION; DRUG EXPOSURE; DRUG RESPONSE; DYSKINESIA; FEMALE; LOCOMOTION; MALE; MARMOSET; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; REVIEW;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; CARBIDOPA; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; LOCOMOTION; MALE; PARKINSONIAN DISORDERS; PULSE THERAPY, DRUG; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 0013045518     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10394     Document Type: Review

References (42)

1. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
2. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994; 9:2-12.
3. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47:S2-S9.
4. Gomez-Mancilla B, Bedard PJ. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413.
5. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000;47:S167-S176.
6. Nutt JG. Clinical pharmacology of levodopa-induced dyskinesia. Ann Neurol 2000;47:S160-S164.
7. Bedard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 1986;379:294-299.
8. Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987;78:273-280.
9. Boyce S, Rupniak NM, Steventon MJ, Iversen SD. Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology (Berl) 1990;102:21-27.
10. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740.
11. Rascol O. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease. J Neurol 2000;247(Suppl. 2):II51-II57.
12. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
13. Kulisevsky J, Lopez-Villegas D, Garcia-Sanchez C, Barbanoj M, Gironell A, Pascual-Sedano B. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients. Clin Neuropharmacol 1998;21:358-362.
14. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(Suppl. 1):23-30.
15. Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevsky J, Malagu S, Weiser R, Rost N. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999;53:573-579.
16. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A 5-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
17. Holloway R, Shoulson I, Kieburtz K, McDermott M, Tariot P. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931-1938.
18. Falardeau P, Bouchard S, Bedard PJ, Boucher R, Di Paolo T. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66.
19. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-241.
20. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000;15:459-466.
21. Pearce RK. L-dopa and dyskinesias in normal monkeys. Mov Disord 1999;14(Suppl. 1):9-12.
22. Togasaki DM, Tan L, Protell P, Di Monte DA, Quik M, Langston JW. Levodopa induces dyskinesias in normal squirrel monkeys. Ann Neurol 2001;50:254-257.
23. Rascol O. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov Disord 1999;14(Suppl. 1):19-32.
24. Blanchet PJ, Calon F, Martel JC, Bedard PJ, Di Paolo T, Walters RR, Piercey MF. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859.
25. Goulet M, Grondin R, Blanchet PJ, Bedard PJ, Di Paolo T. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naïve MPTP monkeys. Brain Res 1996;719:129-137.
26. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
27. Weick BG, Engber TM, Susel Z, Chase TN, Walters JR. Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration. Brain Res 1990;523:16-22.
28. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991;552:113-118.
29. Schuh LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
30. Trugman JM, Hubbard CA, Bennett JP. Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra. Brain Res 1996;725:177-183.
31. Syed N, Murphy J, Zimmerman T, Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338.
32. Ruottinen HM, Rinne UK. A double-blind phaimacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.
33. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-1250.
34. Rose S, Nomoto M, Jackson EA, Gibb WR, Jenner P, Marsden CD. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets. Neuropharmacology 1989;28:1211-1216.
35. Loschmann PA, Smith LA, Lange KW, Jahnig P, Jenner P, Marsden CD. Motor activity following the administration of selective D- and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology (Berl) 1992;109:49-56.
36. Smith LA; Gordin A, Jenner P, Marsden CD. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov Disord 1997;12:935-945.
37. Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrook MA. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 1987;14:428-435.
38. Bedard PJ, Mancilla BG, Blanchette P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
39. Cedarbaum JM, Leger G, Guttman M. Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin Neuropharmacol 1991;14:330-342.
40. Kaakkola S, Wurtman RJ. Effects of catechol-O-methyltransferase inhibitors and L3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. J Neurochem 1993;60:137-144.
41. Napolitano A, Zurcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 1995;273:215-221.
42. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-27.